Successful collaboration has accelerated the computational flow of MaxQ AI’s Accipio Medical Diagnostics Platform
MaxQ AI, a medical diagnostic AI company, announced that through its collaboration with Intel, it was able to triple the computational performance of its Accipio intracranial hemorrhage (ICH) and stroke detection platform, enabling clinicians to prioritize critical patients and provide faster, near real-time ICH diagnosis. MaxQ AI’s Accipio platform uses vision algorithms comprised of machine learning neural networks capable of reading all major CT OEMs’ non-contrast CT with a goal of providing speed and confidence in diagnosing suspected ICH. Accipio Ix™ has received both FDA clearance and CE Mark certification, and is being deployed through major OEM CT and PACS partners to the global acute healthcare space.
Medical errors are the third-greatest cause of death in the U.S.i As an example, stroke patients are misdiagnosed in emergency rooms between 9 percent and 30 percent of the time.ii It is projected that there will be 3.4 million stroke victims by 2030, which will cause loss or extreme hardships for patients and their families while generating $240 billionin total direct and indirect costs.iii
MaxQ is committed to harnessing the power of AI to raise the level of acute care in hospitals with expert results that can potentially save lives, improve quality and lower healthcare costs. Based on deep-learning technologies, the Accipio lx software platform is trained to automatically analyze CT images for ICH. The acute imaging AI engine leverages deep vision and cognitive analytics to compare billions of data points to identify even rare, long-tail anomalies. The platform is capable of combining the full richness of medical imaging along with other relevant patient data.
MaxQ’s Accipio Ix reduces the time needed to detect hemorrhages, enabling physicians to prioritize patient care when time is of the utmost importance. MaxQ AI’s Accipio Ix can now achieve over 300 percent acceleration in the computational flow of algorithms on Intel AI, without impacting detection accuracy.
“Many of our world-class algorithms are written using the Intel Distribution of OpenVINO™ Toolkit and optimized for Intel Processors, which accelerates the computational flow of the MaxQ Platform and enables clinicians to prioritize critical patients,” said Robert Mehler, Co-Founder and Chief Operating Officer of MaxQ AI.
The MaxQ Accipio platform is powered by Intel AI technologies including Intel Xeon and Intel Core™ CPUs and Intel Movidius™ VPUs, and is optimized with the Intel Distribution of OpenVINO™ toolkit and Intel performance libraries. MaxQ’s Accipio platform is designed to be highly sensitive to the presence of acute ICH – commonly known as a brain bleed – identifying and prioritizing patients with ICH for the treating physician. The rapid processing time enables doctors to make faster, near-real-time decisions when diagnosing stroke, traumatic brain injury and ICH, where every minute counts.